Skip to main content
SpringerLink
Log in

Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer

  • Living reference work entry
  • First Online:
Handbook of Cancer and Immunology

  • 46 Accesses

Abstract

The development of increased knowledge of the interaction between cancer cells, immune cells, and the tumor microenvironment is of special interest because immune and niche-related cells hold great potential to destroy malignant cells. However, a peculiar ecosystem also nurses malignant clones; thus, the regulation and therapeutic activation of anti-angiogenesis with the aim of modulating the function of malignant vessels as immune gatekeepers in the cancer niche still represent evolving avenues in oncology. The functional characterization of molecular targets for pharmacological and immunological tumor therapy in the malignant advanced neoplasia pioneered the potential to elucidate the expression of immunosuppressive proteins by clonal cells. Thus, the activation of oncogenic signaling that can be interrupted by combinatorial approaches targeting the immune-patrolling cells and the vascular system at the same time. This chapter aims to review the regulation and therapeutic intervention for immunotherapy, starting from a robust pathobiological background. A combinatorial approach aims to unleash anti-tumor immunity while halting the cancer-associated angiogenesis. The need for an immunogram has also been uncovered to be the basis for next generation immunotherapy and immunodiagnostic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G (2017) Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 9(385):eaak9679. https://doi.org/10.1126/scitranslmed.aak9679

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE (2019) Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res 79(6):1214–1225. https://doi.org/10.1158/0008-5472.CAN-18-1127

    Article  CAS  PubMed  Google Scholar 

  • Antonio G, Oronzo B, Vito L, Angela C, Antonel-la A, Roberto C, Giovanni SA, Antonella L (2020) Immune system and bone microenvironment: rationale for targeted cancer therapies. Oncotarget 11(4). https://doi.org/10.18632/oncotarget.27439

  • Argentiero A, De Summa S, Di Fonte R, Iacobazzi RM, Porcelli L, Da Vià M, Brunetti O, Azzariti A, Silvestris N, Solimando AG (2019a) Gene expression comparison between the lymph node-positive and -negative reveals a peculiar immune microenvironment signature and a Theranostic role for WNT targeting in pancreatic ductal adenocarcinoma: a pilot study. Cancers 11(7). https://doi.org/10.3390/cancers11070942

  • Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, Santini D, Silvestris N, Vacca A (2019b) Skeletal metastases of unknown primary: biological landscape and clinical overview. Cancers 11(9). https://doi.org/10.3390/cancers11091270

  • Argentiero A, Solimando AG, Krebs M, Leone P, Susca N, Brunetti O, Racanelli V, Vacca A, Silvestris N (2020a) Anti-angiogenesis and immunotherapy: novel paradigms to envision tailored approaches in renal cell-carcinoma. J Clin Med 9(5). https://doi.org/10.3390/jcm9051594

  • Argentiero A, Solimando AG, Ungaro V, Laforgia M, Strippoli S, Pinto D, Negri A, Ferraiuolo S, Zito A, Guida M (2020b) Case report: lymphocytosis associated with fatal hepatitis in a Thymoma patient treated with anti-PD1: new insight into the immune-related storm. Front Oncol 10:583781. https://doi.org/10.3389/fonc.2020.583781

    Article  PubMed  PubMed Central  Google Scholar 

  • Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19(3):405–415. https://doi.org/10.1016/S1470-2045(18)30081-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu L-F, Kadel E, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T (2021) Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun 12(1):3969. https://doi.org/10.1038/s41467-021-24112-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bellone M, Calcinotto A (2013) Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 3:231. https://doi.org/10.3389/fonc.2013.00231

    Article  PubMed  PubMed Central  Google Scholar 

  • Blank CU, Haanen JB, Ribas A, Schumacher TN (2016) Cancer immunology. The “cancer immunogram”. Science 352(6286):658–660. https://doi.org/10.1126/science.aaf2834

    Article  CAS  PubMed  Google Scholar 

  • Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S (2019) Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol 10:168. https://doi.org/10.3389/fimmu.2019.00168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129(9):2158–2170. https://doi.org/10.1002/ijc.25863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O (2007) Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol Baltim Md 178(3):1505–1511. https://doi.org/10.4049/jimmunol.178.3.1505

    Article  CAS  Google Scholar 

  • Brandl A, Solimando A, Mokhtari Z, Tabares P, Medler J, Manz H, Da Vià MC, Croci GA, Kurzwart M, Thusek S, Schneider T, Ebert R, Jakob F, Einsele H, Beilhack A (2021) Junctional adhesion molecule-C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans. Blood Adv:bloodadvances.2021004354. https://doi.org/10.1182/bloodadvances.2021004354

  • Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, Agdashian D, Zhang Q, Korangy F, Greten TF (2018) Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother CII 67(8):1305–1315. https://doi.org/10.1007/s00262-018-2190-4

    Article  CAS  PubMed  Google Scholar 

  • Bukhari S, Ward K, Styler M (2020) Hepatocellular carcinoma: first manifestation as solitary humeral bone metastasis. Case Rep Oncol Med 2020:8254236. https://doi.org/10.1155/2020/8254236

  • Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P (2016) Ipilimumab and Bevacizumab in Glioblastoma. Clin Oncol R Coll Radiol G B 28(10):622–626. https://doi.org/10.1016/j.clon.2016.04.042

    Article  CAS  Google Scholar 

  • Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol 28(6):1368–1379. https://doi.org/10.1093/annonc/mdx108

    Article  CAS  Google Scholar 

  • Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718):382–386. https://doi.org/10.1038/s41586-018-0392-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI (2018) Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol 19(4):451–460. https://doi.org/10.1016/S1470-2045(18)30107-4

    Article  CAS  PubMed  Google Scholar 

  • Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587. https://doi.org/10.1126/science.aao4572

    Article  CAS  PubMed  Google Scholar 

  • Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LGT, Riaz N, Lenz TL, Chan TA (2019) Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med 25(11):1715–1720. https://doi.org/10.1038/s41591-019-0639-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R (2020) Combining immune checkpoint inhibitors with anti-Angiogenic agents. J Clin Med 9(3). https://doi.org/10.3390/jcm9030675

  • Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ (2021) Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun 12(1):5137. https://doi.org/10.1038/s41467-021-25432-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cortes-Ciriano I, Lee S, Park W-Y, Kim T-M, Park PJ (2017) A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 8:15180. https://doi.org/10.1038/ncomms15180

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Da Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM (2020 Feb) CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement. Oncologist 25(2):112–118. https://doi.org/10.1634/theoncologist.2019-0356

    Article  CAS  PubMed  Google Scholar 

  • Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7(1):278. https://doi.org/10.1186/s40425-019-0768-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Derakhshani A, Hashemzadeh S, Asadzadeh Z, Shadbad MA, Rasibonab F, Safarpour H, Jafarlou V, Solimando AG, Racanelli V, Singh PK, Najafi S, Javadrashid D, Brunetti O, Silvestris N, Baradaran B (2021) Cytotoxic T-lymphocyte Antigen-4 in colorectal cancer: another therapeutic side of Capecitabine. Cancers 13(10):2414. https://doi.org/10.3390/cancers13102414

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Desantis V, Saltarella I, Lamanuzzi A, Melaccio A, Solimando AG, Mariggiò MA, Racanelli V, Paradiso A, Vacca A, Frassanito MA (2020) MicroRNAs-based Nano-strategies as new therapeutic approach in multiple myeloma to overcome disease progression and drug resistance. Int J Mol Sci 21(9):E3084. https://doi.org/10.3390/ijms21093084

    Article  CAS  Google Scholar 

  • Dirkx AEM, Oude Egbrink MGA, Castermans K, van der Schaft DWJ, Thijssen VLJL, Dings RPM, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JCA, Griffioen AW (2006) Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J Off Publ Fed Am Soc Exp Biol 20(6):621–630. https://doi.org/10.1096/fj.05-4493com

    Article  CAS  Google Scholar 

  • Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18(6):345–362. https://doi.org/10.1038/s41571-021-00473-5

    Article  CAS  PubMed  Google Scholar 

  • Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J (2020) Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol 6(3):375–384. https://doi.org/10.1001/jamaoncol.2019.5367

    Article  PubMed  Google Scholar 

  • Farolfi A, Schepisi G, Conteduca V, Burgio SL, Lolli C, De Giorgi U (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Expert Opin Drug Metab Toxicol 12(9):1089–1096. https://doi.org/10.1080/17425255.2016.1214713

    Article  CAS  PubMed  Google Scholar 

  • Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Lim HY, Kudo M, Breder VV, Merle P, Kaseb AO, Li D, Verret W, Shao H, Liu J, Li L, Zhu AX, Cheng A-L (2021) IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 39(3_suppl):267–267. https://doi.org/10.1200/JCO.2021.39.3_suppl.267

  • Fucà G, de Braud F, Di Nicola M (2018) Immunotherapy-based combinations: an update. Curr Opin Oncol 30(5):345–351. https://doi.org/10.1097/CCO.0000000000000466

    Article  CAS  PubMed  Google Scholar 

  • Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O’Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D’Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205. https://doi.org/10.1186/1479-5876-10-205

    Article  PubMed  PubMed Central  Google Scholar 

  • Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19(6):1189–1201. https://doi.org/10.1016/j.celrep.2017.04.031

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K (2017) Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov 7(12):1420–1435. https://doi.org/10.1158/2159-8290.CD-17-0593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C (2019) The clinical role of the TME in solid cancer. Br J Cancer 120(1):45–53. https://doi.org/10.1038/s41416-018-0327-z

    Article  PubMed  Google Scholar 

  • Gnoni A, Licchetta A, Memeo R, Argentiero A, Solimando AG, Longo V, Delcuratolo S, Brunetti O (2019) Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies. Medicina (Mex) 55(12):754. https://doi.org/10.3390/medicina55120754

    Article  Google Scholar 

  • Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R (2019) Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res 7(10):1570–1573. https://doi.org/10.1158/2326-6066.CIR-19-0149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grant MJ, Herbst RS, Goldberg SB (2021) Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 18(10):625–644. https://doi.org/10.1038/s41571-021-00520-1

    Article  PubMed  Google Scholar 

  • Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of Lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 33(25):2803–2811. https://doi.org/10.1200/JCO.2014.59.5363

    Article  CAS  Google Scholar 

  • Gunturi A, McDermott DF (2015) Nivolumab for the treatment of cancer. Expert Opin Investig Drugs 24(2):253–260. https://doi.org/10.1517/13543784.2015.991819

    Article  CAS  PubMed  Google Scholar 

  • Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535

    Article  PubMed  PubMed Central  Google Scholar 

  • He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R (2018) Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol 245(2):209–221. https://doi.org/10.1002/path.5080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2(7):632–642. https://doi.org/10.1158/2326-6066.CIR-14-0053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109(43):17561–17566. https://doi.org/10.1073/pnas.1215397109

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Goel S, Duda DG, Fukumura D, Jain RK (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73(10):2943–2948. https://doi.org/10.1158/0008-5472.CAN-12-4354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Inamura K (2020) Roles of microbiota in response to cancer immunotherapy. Semin Cancer Biol 65:164–175. https://doi.org/10.1016/j.semcancer.2019.12.026

    Article  CAS  PubMed  Google Scholar 

  • Incorvaia L, Badalamenti G, Rinaldi G, Iovanna JL, Olive D, Swayden M, Terruso L, Vincenzi B, Fulfaro F, Bazan V, Russo A, Fanale D (2019) Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? Ther Adv Med Oncol 11:1758835919848872. https://doi.org/10.1177/1758835919848872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, Brando C, Rizzo M, Messina C, Rediti M, Russo A, Bazan V, Iovanna JL (2020) Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Onco Targets Ther 9(1):1832348. https://doi.org/10.1080/2162402X.2020.1832348

    Article  Google Scholar 

  • Jridi I, Catacchio I, Majdoub H, Shahbazzadeh D, El Ayeb M, Frassanito MA, Solimando AG, Ribatti D, Vacca A, Borchani L (2017) The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from Hemiscorpius lepturus scorpion venom, mediates the antiangiogenic effect of the whole protein. Toxicon Off J Int Soc Toxinology 126:38–46. https://doi.org/10.1016/j.toxicon.2016.12.001

    Article  CAS  Google Scholar 

  • Kawashima A, Uemura M, Nonomura N (2019) Importance of multiparametric evaluation of immune-related T-cell markers in renal-cell carcinoma. Clin Genitourin Cancer 17(6):e1147–e1152. https://doi.org/10.1016/j.clgc.2019.07.021

    Article  PubMed  Google Scholar 

  • Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM (2015) Pembrolizumab. J Immunother Cancer 3:36. https://doi.org/10.1186/s40425-015-0078-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Krebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, Hatzichristodoulou G, Kneitz S, Bargou R, Kübler H, Schilling B, Spahn M, Kneitz B (2020) miR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from Sunitinib in vitro. J Clin Med 9(3). https://doi.org/10.3390/jcm9030670

  • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee MS, Ryoo B-Y, Hsu C-H, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee K-H, GO30140 investigators (2020) Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 21(6):808–820. https://doi.org/10.1016/S1470-2045(20)30156-X

  • Leone P, Di Lernia G, Solimando AG, Cicco S, Saltarella I, Lamanuzzi A, Ria R, Frassanito MA, Ponzoni M, Ditonno P, Dammacco F, Racanelli V, Vacca A (2019) Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients. Onco Targets Ther 8(1):e1486949. https://doi.org/10.1080/2162402X.2018.1486949

    Article  Google Scholar 

  • Leone P, Solimando AG, Malerba E, Fasano R, Buonavoglia A, Pappagallo F, De Re V, Argentiero A, Silvestris N, Vacca A, Racanelli V (2020) Actors on the scene: immune cells in the myeloma niche. Front Oncol 10:599098. https://doi.org/10.3389/fonc.2020.599098

    Article  PubMed  PubMed Central  Google Scholar 

  • Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V (2021) The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment. Vaccine 9(5):532. https://doi.org/10.3390/vaccines9050532

    Article  CAS  Google Scholar 

  • Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH (2019) Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol 145(10):2541–2546. https://doi.org/10.1007/s00432-019-02982-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu X-D, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E (2015) Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3(9):1017–1029. https://doi.org/10.1158/2326-6066.CIR-14-0244

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y, Li K (2020a) Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 11(5):309. https://doi.org/10.1038/s41419-020-2511-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu X, Guo C-Y, Tou F-F, Wen X-M, Kuang Y-K, Zhu Q, Hu H (2020b) Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis. Int J Cancer 147(1):116–127. https://doi.org/10.1002/ijc.32744

    Article  CAS  PubMed  Google Scholar 

  • Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol Off J Eur Soc Med Oncol 30(8):1279–1288. https://doi.org/10.1093/annonc/mdz158

    Article  CAS  Google Scholar 

  • Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob J-J, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC (2019) Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20(8):1083–1097. https://doi.org/10.1016/S1470-2045(19)30274-8

    Article  CAS  PubMed  Google Scholar 

  • Maccalli C, Volontè A, Cimminiello C, Parmiani G (2014) Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer Oxf Engl 1990 50(3):649–655. https://doi.org/10.1016/j.ejca.2013.11.014

    Article  CAS  Google Scholar 

  • Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20(5):711–718. https://doi.org/10.1016/S1470-2045(19)30020-8

    Article  CAS  PubMed  Google Scholar 

  • Marquardt A, Solimando AG, Kerscher A, Bittrich M, Kalogirou C, Kübler H, Rosenwald A, Bargou R, Kollmannsberger P, Schilling B, Meierjohann S, Krebs M (2021) Subgroup-independent mapping of renal cell carcinoma-machine learning reveals prognostic mitochondrial gene signature beyond histopathologic boundaries. Front Oncol 11:621278. https://doi.org/10.3389/fonc.2021.621278

    Article  PubMed  PubMed Central  Google Scholar 

  • Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I (1950) Girard J-P (2013) high endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. J Immunol Baltim Md 191(4):2001–2008. https://doi.org/10.4049/jimmunol.1300872

    Article  CAS  Google Scholar 

  • Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104–108. https://doi.org/10.1126/science.aao3290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T (2018) Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 24(6):749–757. https://doi.org/10.1038/s41591-018-0053-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin S-Y (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol Off J Eur Soc Med Oncol 32(5):661–672. https://doi.org/10.1016/j.annonc.2021.02.006

    Article  CAS  Google Scholar 

  • McKean WB, Moser JC, Rimm D, Hu-Lieskovan S (2020) Biomarkers in precision cancer immunotherapy: promise and challenges. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 40:e275–e291. https://doi.org/10.1200/EDBK_280571

    Article  Google Scholar 

  • Memeo R, Pessaux P, Silvestris N, Brunetti O, Solimando AG, Gardini AC (2021) Hepatocellular Cancer. In: Russo A, Peeters M, Incorvaia L, Rolfo C (eds) Practical medical oncology textbook. Springer, Cham, pp 689–706

    Chapter  Google Scholar 

  • Mennitto A, Huber V, Ratta R, Sepe P, de Braud F, Procopio G, Guadalupi V, Claps M, Stellato M, Daveri E, Rivoltini L, Verzoni E (2020) Angiogenesis and immunity in renal carcinoma: can we turn an unhappy relationship into a happy marriage? J Clin Med 9(4):E930. https://doi.org/10.3390/jcm9040930

    Article  CAS  Google Scholar 

  • Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm M-O, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, MB MH, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Naboush A, Roman CAJ, Shapira I (2017) Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge. J Investig Med Off Publ Am Fed Clin Res 65(4):754–758. https://doi.org/10.1136/jim-2016-000342

    Article  Google Scholar 

  • Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J (2019) PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 14(6):1021–1031. https://doi.org/10.1016/j.jtho.2019.02.008

    Article  CAS  Google Scholar 

  • Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 96(5):2233–2238. https://doi.org/10.1073/pnas.96.5.2233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Olivier T, Fernandez E, Labidi-Galy I, Dietrich P-Y, Rodriguez-Bravo V, Baciarello G, Fizazi K, Patrikidou A (2021) Redefining cancer of unknown primary: is precision medicine really shifting the paradigm? Cancer Treat Rev 97:102204. https://doi.org/10.1016/j.ctrv.2021.102204

    Article  CAS  PubMed  Google Scholar 

  • Oršolić N (2012) Bee venom in cancer therapy. Cancer Metastasis Rev 31(1–2):173–194. https://doi.org/10.1007/s10555-011-9339-3

    Article  CAS  PubMed  Google Scholar 

  • Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reiss KA, Forde PM, Brahmer JR (2014) Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy 6(4):459–475. https://doi.org/10.2217/imt.14.9

    Article  CAS  PubMed  Google Scholar 

  • Ria R, Prete F, Melaccio A, Di Meo G, Saltarella I, Solimando AG, Gurrado A, Ferraro V, Pasculli A, Sgaramella LI, Racanelli V, Vacca A, Testini M (2021) Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: potential for new biomarkers? Surgery 169(1):27–33. https://doi.org/10.1016/j.surg.2020.03.031

    Article  PubMed  Google Scholar 

  • Ribatti D, Solimando AG, Pezzella F (2021) The anti-VEGF(R) drug discovery legacy: improving attrition rates by breaking the vicious cycle of angiogenesis in cancer. Cancers 13(14):3433. https://doi.org/10.3390/cancers13143433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang Y-H, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019a) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ, IMmotion151 Study Group (2019b) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Lond Engl 393(10189):2404–2415. https://doi.org/10.1016/S0140-6736(19)30723-8

    Article  Google Scholar 

  • Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob J-J, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen T-T, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526. https://doi.org/10.1056/NEJMoa1104621

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol 8(10):577–585. https://doi.org/10.1038/nrclinonc.2011.116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97. https://doi.org/10.1126/science.aan3706

    Article  CAS  PubMed  Google Scholar 

  • Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell’Aquila E, Anesi C, Silvestris N, Argentiero A, Solimando AG, Vincenzi B, Tonini G, Santini D (2020) Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res CR 39(1):95. https://doi.org/10.1186/s13046-020-01601-2

    Article  CAS  PubMed  Google Scholar 

  • Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggiò MA, Vacca A, Frassanito MA (2020) Mechanisms of resistance to anti-CD38 Daratumumab in multiple myeloma. Cell 9(1):167. https://doi.org/10.3390/cells9010167

    Article  CAS  Google Scholar 

  • Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD (2015) Pooled analysis of Long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 33(17):1889–1894. https://doi.org/10.1200/JCO.2014.56.2736

    Article  CAS  Google Scholar 

  • Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller H-J, Ooi C-H, Laoui D, De Palma M (2017) Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med 9(385):eaak9670. https://doi.org/10.1126/scitranslmed.aak9670

    Article  CAS  PubMed  Google Scholar 

  • Shadbad MA, Safaei S, Brunetti O, Derakhshani A, Lotfinejad P, Mokhtarzadeh A, Hemmat N, Racanelli V, Solimando AG, Argentiero A, Silvestris N, Baradaran B (2021) A systematic review on the therapeutic potentiality of PD-L1-inhibiting MicroRNAs for triple-negative breast cancer: toward single-cell sequencing-guided biomimetic delivery. Genes 12(8):1206. https://doi.org/10.3390/genes12081206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70(15):6171–6180. https://doi.org/10.1158/0008-5472.CAN-10-0153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Silvestris N, Argentiero A, Brunetti O, Sonnessa M, Colonna F, Delcuratolo S, Luchini C, Scarpa A, Lonardi S, Nappo F, Fassan M, Solimando AG, Fucci L, Saponaro C (2021) PD-L1 and notch as novel biomarkers in pancreatic Sarcomatoid carcinoma: a pilot study. Expert Opin Ther Targets 25:1007. https://doi.org/10.1080/14728222.2021.2011859

    Article  CAS  PubMed  Google Scholar 

  • Siu LL, Ivy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL (2017) Challenges and opportunities in adapting clinical trial Design for Immunotherapies. Clin Cancer Res Off J Am Assoc Cancer Res 23(17):4950–4958. https://doi.org/10.1158/1078-0432.CCR-16-3079

    Article  Google Scholar 

  • Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H (2019) High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. J Clin Med 8(7):E997. https://doi.org/10.3390/jcm8070997

    Article  CAS  Google Scholar 

  • Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Andreas R, Martin Kortüm K, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A (2020) Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica 106(7):1943–1956. https://doi.org/10.3324/haematol.2019.239913

  • Solimando AG, Crudele L, Leone P, Argentiero A, Guarascio M, Silvestris N, Vacca A, Racanelli V (2020a) Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci 21(9):3054. https://doi.org/10.3390/ijms21093054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Solimando AG, Summa SD, Vacca A, Ribatti D (2020b) Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling. Cancers 12(11):3380. https://doi.org/10.3390/cancers12113380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Solimando AG, Susca N, Borrelli P, Prete M, Lauletta G, Pappagallo F, Buono R, Inglese G, Forina BM, Bochicchio D, Capobianco M, Carrieri V, Cicco S, Leone P, Silvestris N, Saracino A, Ria R, Procacci V, Migliore G, Vacca A, Racanelli V (2020c) Short-term variations in neutrophil-to-lymphocyte and urea-to-creatinine ratios anticipate intensive care unit admission of COVID-19 patients in the emergency department. Front Med 7:625176. https://doi.org/10.3389/fmed.2020.625176

    Article  Google Scholar 

  • Solimando AG, Susca N, Argentiero A, Brunetti O, Leone P, De Re V, Fasano R, Krebs M, Petracci E, Azzali I, Nanni O, Silvestris N, Vacca A, Racanelli V (2021) Second-line treatments for advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Clin Exp Med. https://doi.org/10.1007/s10238-021-00727-7

  • Solimando AG, Kalogirou C, Krebs M (2022) Angiogenesis as therapeutic target in metastatic prostate cancer - narrowing the gap between bench and bedside. Front Immunol 13:842038. https://doi.org/10.3389/fimmu.2022.842038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Song L, Pan D, Zhou R (2020a) Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: a case report and review of the literature. Mol Clin Oncol 13(5):54. https://doi.org/10.3892/mco.2020.2124

    Article  PubMed  PubMed Central  Google Scholar 

  • Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B (2020b) Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol 11:1956. https://doi.org/10.3389/fimmu.2020.01956

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Taylor MH, Rasco DW, Brose MS, Vogelzang NJ, Richey SL, Cohn AL, Richards DA, Stepan DE, Dutcus CE, Guo M, Shumaker RC, Schmidt EV, Wirth LJ (2018) A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 36(15_suppl):6016–6016. https://doi.org/10.1200/JCO.2018.36.15_suppl.6016

    Article  Google Scholar 

  • Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT, Zhang XH-F (2017) Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544(7649):250–254. https://doi.org/10.1038/nature21724

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287. https://doi.org/10.1038/nrc.2016.36

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23(2):39. https://doi.org/10.1208/s12248-021-00574-0

    Article  PubMed  Google Scholar 

  • Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-Sela G (2018) The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol Northwood Lond Engl 35(3):25. https://doi.org/10.1007/s12032-018-1080-0

    Article  CAS  Google Scholar 

  • Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT (2021) Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 12(1):729. https://doi.org/10.1038/s41467-021-20935-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vanhersecke L, Brunet M, Guégan J-P, Rey C, Bougouin A, Cousin S, Le Moulec S, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria J-C, Bellera C, Sofeu C, Bessede A, Fridman WH, Le Loarer F, Italiano A (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2(8):794–802. https://doi.org/10.1038/s43018-021-00232-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF (2016) Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 7:12624. https://doi.org/10.1038/ncomms12624

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC (2019) Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-Centre, single-arm, phase 2 trial. Lancet Oncol 20(6):837–848. https://doi.org/10.1016/S1470-2045(19)30153-6

    Article  CAS  PubMed  Google Scholar 

  • Xu Y, Kroft SH, McKenna RW, Aquino DB (2001) Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol 112(4):945–949. https://doi.org/10.1046/j.1365-2141.2001.02649.x

    Article  CAS  PubMed  Google Scholar 

  • Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F (2021) T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 12(1):1402. https://doi.org/10.1038/s41467-021-21619-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang J, Yan J, Liu B (2018) Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 9:978. https://doi.org/10.3389/fimmu.2018.00978

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA (2021) Development of immunotherapy combination strategies in cancer. Cancer Discov 11(6):1368–1397. https://doi.org/10.1158/2159-8290.CD-20-1209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao S, Jiang T, Li X, Zhou C (2017) OA11.07 combining anti-angiogenesis and immunotherapy enhances antitumor effect by promoting immune response in lung cancer. J Thorac Oncol 12(1):S288. https://doi.org/10.1016/j.jtho.2016.11.293

    Article  Google Scholar 

  • Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y (2018) Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104–2115. https://doi.org/10.1172/JCI96582

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan C (2021) Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol OncolJ Hematol Oncol 14(1):156. https://doi.org/10.1186/s13045-021-01164-5

    Article  Google Scholar 

  • Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59–73. https://doi.org/10.1038/nri2216

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge Biorender for providing comprehensive medical and biological figures and datasets that are fruitful for the international scientific community. The authors’ publishing license has been deposited under agreement number ZP25DKUDME.

Author information

Authors and Affiliations

  1. Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, Bari, Italy

    Antonio G. Solimando

  2. Medical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, Bari, Italy

    Antonio G. Solimando

  3. Department of Translational Biomedicine and Neuroscience, School of Medicine, Aldo Moro University of Bari, Bari, Italy

    Domenico Ribatti

Authors
  1. Antonio G. Solimando
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenico Ribatti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Antonio G. Solimando or Domenico Ribatti .

Editor information

Editors and Affiliations

  1. Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Sweden

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Solimando, A.G., Ribatti, D. (2023). Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_163-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80962-1_163-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80962-1

  • Online ISBN: 978-3-030-80962-1

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation